Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darifenacin in Elderly Patients with Overactive Bladder
NCT00171184Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) comparing Darifenacin with Placebo (2 arms). Primary endpoint: Change from baseline in number of urge urinary incontinence episodes per week at 12 weeks. Started Apr 2005; status: completed.
02
Drugs
darifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00171184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171184.